KURN Profitability Analysis: Past Growth, Margins, Return on Capital, Free Cash Flow, and more - Kuros Biosciences AG - Alpha Spread

Kuros Biosciences AG
SIX:KURN

Watchlist Manager
Kuros Biosciences AG Logo
Kuros Biosciences AG
SIX:KURN
Watchlist
Price: 21.7 CHF 9.49%
Market Cap: 794.3m CHF
Have any thoughts about
Kuros Biosciences AG?
Write Note

Profitability Summary

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Kuros Biosciences AG

Revenue
52.5m CHF
Cost of Revenue
-11m CHF
Gross Profit
41.6m CHF
Operating Expenses
-50.8m CHF
Operating Income
-9.2m CHF
Other Expenses
336k CHF
Net Income
-8.9m CHF

Margins Comparison
Kuros Biosciences AG Competitors

Country Company Market Cap Gross
Margin
Operating
Margin
Net
Margin
CH
Kuros Biosciences AG
SIX:KURN
797.8m CHF
79%
-18%
-17%
US
Abbvie Inc
NYSE:ABBV
342.9B USD
67%
29%
10%
US
Amgen Inc
NASDAQ:AMGN
176.4B USD
63%
20%
10%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.3B USD
86%
41%
-5%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
112.8B USD
87%
31%
32%
US
Gilead Sciences Inc
NASDAQ:GILD
105.8B USD
77%
37%
4%
US
Epizyme Inc
F:EPE
94.1B EUR
76%
-370%
-392%
AU
CSL Ltd
ASX:CSL
144.6B AUD
52%
26%
18%
US
Seagen Inc
F:SGT
39.3B EUR
75%
-33%
-33%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
36.4B USD
87%
4%
-3%
KY
Beigene Ltd
SSE:688235
241B CNY
84%
-30%
-20%
Country CH
Market Cap 797.8m CHF
Gross Margin
79%
Operating Margin
-18%
Net Margin
-17%
Country US
Market Cap 342.9B USD
Gross Margin
67%
Operating Margin
29%
Net Margin
10%
Country US
Market Cap 176.4B USD
Gross Margin
63%
Operating Margin
20%
Net Margin
10%
Country US
Market Cap 124.3B USD
Gross Margin
86%
Operating Margin
41%
Net Margin
-5%
Country US
Market Cap 112.8B USD
Gross Margin
87%
Operating Margin
31%
Net Margin
32%
Country US
Market Cap 105.8B USD
Gross Margin
77%
Operating Margin
37%
Net Margin
4%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Operating Margin
-370%
Net Margin
-392%
Country AU
Market Cap 144.6B AUD
Gross Margin
52%
Operating Margin
26%
Net Margin
18%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Operating Margin
-33%
Net Margin
-33%
Country US
Market Cap 36.4B USD
Gross Margin
87%
Operating Margin
4%
Net Margin
-3%
Country KY
Market Cap 241B CNY
Gross Margin
84%
Operating Margin
-30%
Net Margin
-20%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Kuros Biosciences AG Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CH
Kuros Biosciences AG
SIX:KURN
797.8m CHF
-14%
-11%
-14%
-19%
US
Abbvie Inc
NYSE:ABBV
342.9B USD
54%
4%
16%
12%
US
Amgen Inc
NASDAQ:AMGN
176.4B USD
49%
3%
9%
8%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
124.3B USD
-3%
-2%
25%
-84%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
112.8B USD
17%
13%
14%
17%
US
Gilead Sciences Inc
NASDAQ:GILD
105.8B USD
5%
2%
23%
13%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
AU
CSL Ltd
ASX:CSL
144.6B AUD
16%
7%
12%
9%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
36.4B USD
35%
-2%
4%
9%
KY
Beigene Ltd
SSE:688235
241B CNY
-17%
-11%
-23%
-46%
Country CH
Market Cap 797.8m CHF
ROE
-14%
ROA
-11%
ROCE
-14%
ROIC
-19%
Country US
Market Cap 342.9B USD
ROE
54%
ROA
4%
ROCE
16%
ROIC
12%
Country US
Market Cap 176.4B USD
ROE
49%
ROA
3%
ROCE
9%
ROIC
8%
Country US
Market Cap 124.3B USD
ROE
-3%
ROA
-2%
ROCE
25%
ROIC
-84%
Country US
Market Cap 112.8B USD
ROE
17%
ROA
13%
ROCE
14%
ROIC
17%
Country US
Market Cap 105.8B USD
ROE
5%
ROA
2%
ROCE
23%
ROIC
13%
Country US
Market Cap 94.1B EUR
ROE
-877%
ROA
-67%
ROCE
-73%
ROIC
-182%
Country AU
Market Cap 144.6B AUD
ROE
16%
ROA
7%
ROCE
12%
ROIC
9%
Country US
Market Cap 39.3B EUR
ROE
-28%
ROA
-21%
ROCE
-27%
ROIC
-39%
Country US
Market Cap 36.4B USD
ROE
35%
ROA
-2%
ROCE
4%
ROIC
9%
Country KY
Market Cap 241B CNY
ROE
-17%
ROA
-11%
ROCE
-23%
ROIC
-46%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top